Biotech
Genetic-analysis technology company CuraGen(CRGN) reported a narrower loss and exceeded analysts' sales expectations in the third quarter, sending its shares higher Thursday.
The company reported a $15.9 million loss, amounting to 29 cents a share, compared with a loss of $22.5 million, or 43 cents a share, a year ago. Analysts were expecting the company to lose 34 cents a share. Revenue reached $9.86 million, up from $5.2 million in the year-ago period and ahead of the consensus estimate of $8.77 million. The stock rose 6.4% to $3.98. CuraGen's majority-owned subsidiary 454 Life Sciences showed strong third-quarter sales, driven by its Genome Sequencer 20 system and record demand for its chemical reagents. "We look forward to the anticipated launch of the Genome Sequencer FLX next year, as we believe the flexibility of this instrument will continue to expand the use of genomic sequencing to a broader range of researchers and drive revenues at 454 Life Sciences," said Frank Armstrong, CuraGen's president and CEO. Additionally, CuraGen improved its full-year guidance by $5 million and now expects a loss of $60 million to $65 million.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |
Connect with TheStreet